Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, et al.
The Lancet (2021) Vol. 397, Iss. 10282, pp. 1351-1362
Open Access | Times Cited: 624

Showing 1-25 of 624 citing articles:

SARS-CoV-2 variants, spike mutations and immune escape
William T. Harvey, Alessandro M. Carabelli, Ben Jackson, et al.
Nature Reviews Microbiology (2021) Vol. 19, Iss. 7, pp. 409-424
Open Access | Times Cited: 3370
Features, Evaluation and Treatment Coronavirus (COVID-19)
Marco Cascella, Michael Rajnik, Arturo Cuomo, et al.
StatPearls (2020)
Closed Access | Times Cited: 2796
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J. Phillips, Thomas White, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 2032-2040
Open Access | Times Cited: 1104
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
John S. Tregoning, Katie E. Flight, Sophie L. Higham, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 10, pp. 626-636
Open Access | Times Cited: 1031
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
Victoria Hall, Sarah Foulkes, Ayoub Saei, et al.
The Lancet (2021) Vol. 397, Iss. 10286, pp. 1725-1735
Open Access | Times Cited: 780
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Chang Liu, Helen M. Ginn, Wanwisa Dejnirattisai, et al.
Cell (2021) Vol. 184, Iss. 16, pp. 4220-4236.e13
Open Access | Times Cited: 708
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
Victoria Hall, Sarah Foulkes, André Charlett, et al.
The Lancet (2021) Vol. 397, Iss. 10283, pp. 1459-1469
Open Access | Times Cited: 649
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Paul T. Heath, Eva Galiza, D. N. Baxter, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 13, pp. 1172-1183
Open Access | Times Cited: 624
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals
Alison Tarke, John Sidney, Nils Methot, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 7, pp. 100355-100355
Open Access | Times Cited: 618
Antibody evasion by the P.1 strain of SARS-CoV-2
Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa, et al.
Cell (2021) Vol. 184, Iss. 11, pp. 2939-2954.e9
Open Access | Times Cited: 616
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros‐Martins, Swantje I. Hammerschmidt, Anne Cossmann, et al.
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1525-1529
Open Access | Times Cited: 412
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R. Falsey, Magdalena E. Sobieszczyk, Ian Hirsch, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 25, pp. 2348-2360
Open Access | Times Cited: 381
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Meng Yuan, Deli Huang, Chang‐Chun D. Lee, et al.
Science (2021) Vol. 373, Iss. 6556, pp. 818-823
Open Access | Times Cited: 362
Novel SARS-CoV-2 variants: the pandemics within the pandemic
Erik Boehm, Ilona Kronig, Richard A. Neher, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 8, pp. 1109-1117
Open Access | Times Cited: 358
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Raches Ella, Siddarth Reddy, William C. Blackwelder, et al.
The Lancet (2021) Vol. 398, Iss. 10317, pp. 2173-2184
Open Access | Times Cited: 333
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2
Olha Puhach, Kenneth Adea, Nicolas Hulo, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1491-1500
Open Access | Times Cited: 323
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
Emma Pritchard, Philippa C. Matthews, Nicole Stoesser, et al.
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1370-1378
Open Access | Times Cited: 317
SARS-CoV-2 viral load and shedding kinetics
Olha Puhach, Benjamin Meyer, Isabella Eckerle
Nature Reviews Microbiology (2022)
Open Access | Times Cited: 302
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
Fatima Amanat, Mahima Thapa, Tinting Lei, et al.
Cell (2021) Vol. 184, Iss. 15, pp. 3936-3948.e10
Open Access | Times Cited: 275
Efficacy and safety of COVID-19 vaccines
Carolina Graña, Lina Ghosn, Theodoros Evrenoglou, et al.
Cochrane library (2022) Vol. 2023, Iss. 3
Open Access | Times Cited: 254
Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)
Abdul Aleem, Abdul Samad, Amy Slenker
(2021) Vol. 01, pp. 01-01
Closed Access | Times Cited: 242
Page 1 - Next Page

Scroll to top